Analysis of FDA-approved imaging agents.
The development of imaging agents was initially driven following the discovery of X-ray technologies, but quickly evolved and expanded to include radiolabeling of cells and tissues to assist disease diagnosis and progression. The first imaging agents preceded the Great War but the field did not gain momentum until the 1950s. The approval rate for imaging NMEs continued at a high level for the remainder of the 20th century, but substantially decreased thereafter. This decline in approval rates corresponds with industry consolidation. Such losses have stabilized, but could have important implications for a field that has conveyed direct benefits to medicine and that could ensure the future of the wider biopharmaceutical industry.
Center for Research Innovation in Biotechnology, Washington University in St. Louis, St Louis, MO, USA. Electronic address: michael.kinch@wustl.edu.
Michael S
MS
Kinch
Department of Radiology, Washington University in St. Louis, St Louis, MO, USA.
Pamela K
PK
Woodard
D064907:Diagnostic Uses of Chemicals; D017277:Drug Approval; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
D064907:Diagnostic Uses of Chemicals